To develop precision medicines that target hypoxic (low oxygen) areasin tumours that conventional chemotherapy, immunotherapy and radiotherapydo not treat hypoxia is recognized as a key pan-cancer resistance mechanism.
Read more about our research
minimal effects compared to conventional cytotoxics
across all tissues, crosses the blood brain barrier
effective, persistent TOPO 2 Inhibitors at target hypoxic sites
OncoTherics Poland Sp. z o.o. ul. prof. Michała Bobrzyńskiego 14 30-348 Kraków Poland
Copyright © 2010 - 2020 All rights reserved